This is how Kineret works

MODE OF ACTION

Kineret is a targeted treatment that neutralises the biological activity of both IL-1α and IL-1β1

Kineret is a recombinant version of the naturally occurring IL-1 receptor antagonist (IL-1Ra). Kineret acts by competitively inhibiting the biological activity of interleukin- 1α (IL-1α) and interleukin-1β (IL-1β), preventing both cytokines from attaching to the IL-1 receptor (IL-1R1) and initiating downstream signalling cascades.1,2 By blocking the interaction between IL-1α/IL-1β and IL-1R1, Kineret interrupts IL- 1-mediated inflammatory processes and alleviates the signs and symptoms of conditions characterised by excessive or dysregulated IL-1 responses.2

Autoinflammatory loop3,4

Kineret neutralises the biologic activity of IL-1α and IL-1β by competitively inhibiting their binding to IL-1R1.1

INFLAMMATORY LOOP
KINERET MODE OF ACTION
FAST ONSET

This is fast onset and short half life

Kineret has high absolute bioavailability after subcutaneous administration; maximum plasma concentrations are reached within 3 to 7 hours and the terminal elimination half-life is 4 to 6 hours. Kineret induces a rapid resolution of systemic features such as fever, rash, and elevation of acute phase reactants.1

Safety

Please refer to current SmPC for more information about the safety and efficacy of Kineret.

Kineret Q&A

How is Kineret administered?
  • Kineret is given in a pre-filled syringe containing 100 mg of anakinra per 0.67 ml (150 mg/ml).1
  • Kineret is given as a subcutaneous injection.1
  • Dosage depends on indication. In children, the dose is determined depending on body weight. Please refer to current SmPC.
How should Kineret be stored?
  • Kineret should be stored in a refrigerator between 2°C and 8°C.1
  • Kineret should not be frozen or shaken.1
  • Kineret should be kept in its original carton and away from light.1

References

  • Swedish Orphan Biovitrum AB (publ). Kineret summary of product characteristics [SmPC]. Latest version available from: https://www.ema.europa.eu/en/documents/ product-information/kineret-epar-product-information_en.pdf
  • Cavalli G, Dinarello CA. Anakinra therapy for non-cancer inflammatory diseases. Front Pharmacol. 2018; 9:1157
  • Cavalli G, Colafrancesco S, Emmi G, et al. Interleukin 1α: a comprehensive review on the role of IL-1α in the pathogenesis and treatment of autoimmune and inflammatory diseases. Autoimmun Rev. 2021;20(3):102763
  • van de Veerdonk, F.L., Netea, M.G. Blocking IL-1 to prevent respiratory failure in COVID-19. Crit Care 24, 445 (2020).